Jet production in deep inelastic ep scattering at HERA

Recent results from jet production in deep inelastic ep scattering at HERA are reviewed. The values of alpha_s(M_z) extracted from a QCD analysis of the data are presented.Comment: 9 pages, 5 figures, talk given at the ``Ringberg workshop: New trends in HERA Physics 2003'

Production of Z0 bosons in elastic and quasi-elastic ep collisions at HERA

Artículo escrito por un elevado número de autores, solo se referencian el que aparece en primer lugar, el nombre del grupo de colaboración, si le hubiere, y los autores pertenecientes a la UAMThe production of Z0 bosons in the reaction ep →eZ0 p(∗), where p(∗) stands for a proton or a lowmass nucleon resonance, has been studied in ep collisions at HERA using the ZEUS detector. The analysis is based on a data sample collected between 1996 and 2007, amounting to 496 pb−1 of integrated luminosity. The Z0 was measured in the hadronic decay mode. The elasticity of the events was ensured by a cut on ηmax < 3.0, where ηmax is the maximum pseudorapidity of energy deposits in the calorimeter defined with respect to the proton beam direction. A signal was observed at the Z0 mass. The cross section of the reaction ep → eZ0 p(∗) was measured to be σ(ep → eZ0 p(∗)) =0.13 ± 0.06(stat.) ± 0.01(syst.) pb, in agreement with the Standard Model prediction of 0.16 pb. This is the first measurement of Z0 production in ep collisionsWe appreciate the contributions to the construction and maintenance of the ZEUS detector of many people who are not listed as authors. The HERA machine group and the DESY computing staff are especially acknowledged for their success in providing excellent operation of the collider and the data-analysis environment. We thank the DESY directorate for their strong support and encouragemen

Pharmacokinetic/pharmacodynamic modelling approaches in paediatric infectious diseases and immunology.

Pharmacokinetic/pharmacodynamic (PKPD) modelling is used to describe and quantify dose-concentration-effect relationships. Within paediatric studies in infectious diseases and immunology these methods are often applied to developing guidance on appropriate dosing. In this paper, an introduction to the field of PKPD modelling is given, followed by a review of the PKPD studies that have been undertaken in paediatric infectious diseases and immunology. The main focus is on identifying the methodological approaches used to define the PKPD relationship in these studies. The major findings were that most studies of infectious diseases have developed a PK model and then used simulations to define a dose recommendation based on a pre-defined PD target, which may have been defined in adults or in vitro. For immunological studies much of the modelling has focused on either PK or PD, and since multiple drugs are usually used, delineating the relative contributions of each is challenging. The use of dynamical modelling of in vitro antibacterial studies, and paediatric HIV mechanistic PD models linked with the PK of all drugs, are emerging methods that should enhance PKPD-based recommendations in the future